http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#Head
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#assertion
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#provenance
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#pubinfo
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#assertion
http://purl.obolibrary.org/obo/DOID_9352
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9352
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB06203
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
http://www.w3.org/2000/01/rdf-schema#label
alogliptin tablets are a dipeptidyl peptidase 4 dpp 4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 1 14 important limitations of use not for treatment of type 1 diabetes or diabetic ketoacidosis 1 1 alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus see clinical studies 14 important limitations of use alogliptin tablets are not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis as it would not be effective in these settings
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB06203
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#provenance
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#pubinfo
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#sig
http://purl.org/nanopub/x/hasSignature
WtbHR3i+5ydBrvRDiyxAg3dRVyLz6Bt2rKWzY2rycP2eKJadAPvbDJI484YUJBidj0oCS9C6v3LKwDha7DQip8yHPJ+CymRhKWBmr9spZF0Rxf+sk6SFIrGPr9Z1AxF35dXKoIOYhfMKoZvZfuMBKe4aFmRPIrBm8djFDL7f4Os=
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://purl.org/dc/terms/created
2021-06-12T14:43:14.540+02:00
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA1v1nK-_4Kad8Di7ZAtU10nYFCorkl1MVl1e5XUqpFE8
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs